Denise Braendgaard: How Partnership is Turning Ambition Into Action
Denise Braendgaard, General Manager at Novo Nordisk Haemophilia and Haemoglobinopathies Foundation, shared Novo Nordisk Haemophilia and Haemoglobinopathies Foundation‘s post on LinkedIn, adding:
“2025 was a year of transformation
At the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation, we expanded our vision and scope, doubling down on our commitment to sustainable access to care for people living with haemophilia and haemoglobinopathies in low- and middle-income countries.
This progress was made possible by our partners: Their leadership, expertise, and dedication continue to drive sustainable, locally anchored impact.
Our Year in Review 2025 captures the milestones, the momentum, and the collective impact achieved together.
I invite you to take a moment to read it and see how partnership is turning ambition into action.”
Novo Nordisk Haemophilia and Haemoglobinopathies Foundation shared a post on LinkedIn:
“The NNHF Year in Review 2025 is here!
This year we focused on ‘Fostering connections and unveiling new horizons’, and the results speak for themselves.
Thanks to our partners, volunteers and funders, we reached new communities, launched meaningful initiatives, and expanded our impact.
Swipe through for some of the highlights, then read the Full Report for stories and outcomes that inspire.”
Other posts featuring Denise Braendgaard on Hemostasis Today.”
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk